Potential Rare Tablet Mix-up

As of September 2012, Endo is aware of several product mix-ups with respect to Endo products (listed below) since 2009, of which all three were detected by pharmacists. We are not aware of any patient having experienced a confirmed product mix-up and there have been no adverse events attributable to a product mix-up. We believe the likelihood of product mix-up reaching a patient is remote.

Endo’s primary concerns are the health, well-being, and continuity of care for patients.

 

For patients currently prescribed any of the following products, a visual guide (PDF) has been provided to verify the appearance of these products. Please review the product name of your prescription to confirm the tablets in your prescription match the tablet images provided:

  • Original Formulation OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets CII
  • OPANA® (oxymorphone hydrochloride) Tablets CII
  • VOLTAREN(R) Gel (diclofenac sodium topical gel) 1%
  • Oxymorphone Hydrochloride Tablets CII
  • PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets CII
  • PERCODAN® (oxycodone hydrochloride and aspirin, USP) Tablets CII
  • ENDOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets CII
  • ENDODAN® (oxycodone hydrochloride and aspirin, USP) Tablets CII
  • Morphine Sulfate Extended-Release Tablets CII
  • ZYDONE® (hydrocodone bitartrate/acetaminophen tablets, USP) CIII